Cancer Research

Rosetta Genomics Completes Acquisition Of Parkway Clinical Laboratories Inc.

+1-646-509-1893 E: investors@rosettagenomics.com Contact: Media, Rachel Spielman, T: +1-212-583-2714, E: ...

Article - Anna Ohlden - Jul 24 2008 - 2:33am

M. D. Anderson To Initiate Clinical Validation Study On Rosetta Genomics' MicroRNA-based Diagnostic Assay Identifying The Origin

investors@rosettagenomics.com Contact: Media & Investors, Ron Kamienchick, T: +1-646-509-1893, E: ...

Article - Anna Ohlden - Aug 11 2008 - 8:33am

Algeta Reports Positive Headline Phase II Data On Pain Palliation With Alpharadin

mark.swallow@citigatedr.co.uk For further information, please contact: Dr. Thomas Ramdahl, CEO, +47-23-00-79-90 / +47-913-91-458 ...

Article - Anna Ohlden - Aug 28 2008 - 4:33am

Top-Line Efficacy Data Presented From Phase 2 Trial Of Alemtuzumab In Multiple Sclerosis

States or +1-703-797-1866 outside the United States. Media Contact: Investor Contact: Bo Piela Patrick ...

Article - Anna Ohlden - Oct 15 2007 - 1:03am

ThromboGenics And BioInvent Receive Approval To Begin Clinical Trials Of TB-403 For The Treatment Of Cancer

+46(0)46-286-85-50, info@bioinvent.com; For further information please contact: ThromboGenics, Prof Desire Collen, ...

Article - Anna Ohlden - Jan 18 2008 - 1:30am

Helsinn Healthcare SA And Riemser Arzneimittel AG Sign A License Agreement For Aloxi(R) (Palonosetron) And Gelclair(R) In German

Vice President Oncology & Hospital Tel: +49-251-980-13-20 E-Mail: heerdt@riemser.de Contact ...

Article - Anna Ohlden - Feb 13 2008 - 6:31am

Genmab Announces Year End 2007 Financial Results

+45-33-44-77-30, M: +45-25-27-47-13, E: hth@genmab.com. Contact: Helle Husted, Sr. Director, Investor Relations, T: ...

Article - Anna Ohlden - Mar 31 2008 - 4:34pm

New Roche Data To Be Presented At ASCO Offers Further Hope For Cancer Patients

16:481-488 For further information please contact: Christine McMenamin, Roche, Tel: +41-61-688-2139, Mob: ...

Article - Anna Ohlden - May 15 2008 - 8:31pm

Gen-Probe Launches In Europe CE-Marked APTIMA(R) HPV Assay For Detection Of Human Papillomavirus

+1-858-410-8673; Victoria Asare-Archer, Porter Novelli, +44-207-853-2269. Contact: Michael Watts, Senior director, ...

Article - Anna Ohlden - May 30 2008 - 8:32am

ThromboGenics And BioInvent Report Positive Phase I Results For Anti-PlGF Cancer Therapeutic TB-403

information please contact: ThromboGenics, Prof Desire Collen, CEO, Tel: +32-(0)-16-34-61-94, Patrik De Haes, ...

Article - Anna Ohlden - Jun 3 2008 - 1:32am